0.215
-0.015
(-6.52%)
May 21 - Close
NYSEMKT
real-time data -
Disclaimer
Currency in USD
| Range | 0.22 - 0.24 |
| 52 week | 0.18 - 0.50 |
| Open | 0.24 |
| Vol / Avg. | 20,243.00/9,283.00 |
| Mkt cap | 10.71M |
| P/E | - |
| Div/yield | - |
| EPS | -0.36 |
| Shares | 49.81M |
| Beta | 2.26 |
| Inst. own | 5% |
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | -94.60% | -195.20% |
| Operating margin | -70.97% | -178.86% |
| EBITD margin | - | -6.85% |
| Return on average assets | -27.52% | -31.45% |
| Return on average equity | -59.53% | -54.38% |
| Employees | 375 | - |
| Carbon Disclosure Rating | - | - |
Address
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Aoxing Pharmaceutical Company, Inc. (Aoxing Pharma), is a pharmaceutical company, which specializes in research, development, manufacturing and distribution of a variety of narcotics and pain-management products and drug-relief medicine. The Company has one operating subsidiary, Hebei Aoxing Pharmaceutical Co., Inc. (Hebei Aoxing).Hebei Aoxing is engaged in developing narcotics and pain management products. The Company owns 95% of the equity in Hebei Aoxing. The Company's product offerings include Zhongtongan,Bismuth Potassium Citrate,Xiaopiling, and Naloxone Hydrochloride.
Officers and directors
| Zhenjiang Yue | Chairman of the Board, Chief Executive Officer | |
| Guoan Zhang | Acting Chief Financial Officer, Senior Vice President - Finance | |
| Guirong Zhou | President - Research and Development | |
| Jun Min | Director | |
| Yang Li | Independent Director | |
| Guozhu Xu | Independent Director |